Veracyte, Inc.

VCYT

Precision medicineHealthcare diagnosticsGenomic analysis

$45.23vs prev close▲+1.63(+3.74%)

$29.4552W Range$60.91

50% from low

+2.44 (+5.75%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

9 buys

Consecutive buys

1M net buy

+$43.7M

≈ +973K shares

Portfolio Weight

0.90%

1M +0.19%p

Holding ETFs

2 ETFs

ARKG · ARKK

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +50.2% · Market value +60.3% · Weight +0.19%p

Trade Intensity

Consecutive buys 9

Basis: 0 sells · 9 buys in 1M · Multi-ETF simultaneous buy · weight +0.19%p increase

Trade Log9-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.10.07	BUY	ARKG	4,913	$43.16	$212.0K
26.10.06	BUY	ARKG	389,509	$44.65	$17.4M
26.10.05	BUY	ARKG	115,472	$47.67	$5.5M
26.10.01	BUY	ARKK	159,376	$44.19	$7.0M
26.09.30	BUY	ARKK	76,392	$46.04	$3.5M
26.09.29	BUY	ARKK	119,416	$46.08	$5.5M
26.09.23	BUY	ARKG	20,908	$43.82	$916.2K
26.09.22	BUY	ARKG	12,583	$43.36	$545.6K
26.09.21	BUY	ARKG	74,878	$41.52	$3.1M
26.09.04	BUY	ARKK	22,144	$42.53	$941.8K
26.08.31	BUY	ARKG	7,031	$43.19	$303.7K
26.08.28	BUY	ARKG · ARKK	213,073	$43.34	$9.2M
26.08.27	BUY	ARKG · ARKK	47,793	$45.25	$2.2M
26.07.28	SELL	ARKK	20,539	$55.65	$1.1M
26.07.08	SELL	ARKG	67,476	$56.12	$3.8M

10.07BUY

4,913

ARKGClose$43.16Est. total$212.0K

10.06BUY

389,509

ARKGClose$44.65Est. total$17.4M

10.05BUY

115,472

ARKGClose$47.67Est. total$5.5M

10.01BUY

159,376

ARKKClose$44.19Est. total$7.0M

09.30BUY

76,392

ARKKClose$46.04Est. total$3.5M

09.29BUY

119,416

ARKKClose$46.08Est. total$5.5M

09.23BUY

20,908

ARKGClose$43.82Est. total$916.2K

09.22BUY

12,583

ARKGClose$43.36Est. total$545.6K

09.21BUY

74,878

ARKGClose$41.52Est. total$3.1M

09.04BUY

22,144

ARKKClose$42.53Est. total$941.8K

08.31BUY

7,031

ARKGClose$43.19Est. total$303.7K

08.28BUY

213,073

ARKG · ARKKClose$43.34Est. total$9.2M

08.27BUY

47,793

ARKG · ARKKClose$45.25Est. total$2.2M

07.28SELL

20,539

ARKKClose$55.65Est. total$1.1M

07.08SELL

67,476

ARKGClose$56.12Est. total$3.8M

1 / 8

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

3,253,090

Portfolio Weight

0.9%

in ETF 2.37%

Est. Value

$155M

30D Net

+$44M

Ray DalioBridgewater Associates

New Buy

28,394

Portfolio Weight

Est. Value

$1M

Change

New position

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Analyst Targets

avg.

$58.42

vs Current ▲ +29.2% upside

Current$45.23

Low ~ High$44.00 ~ $70.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Freedom Capital Markets

Buy

$66.00

+45.92%

—

Maintain

2026-09-15

UBS

Buy

$65.00

+43.71%

—

Maintain

2026-09-09

Piper Sandler

Overweight

$54.00

+19.39%

—

Maintain

2026-08-04

Stephens & Co.

Overweight

$55.00

+21.60%

—

Maintain

2026-08-04

Morgan Stanley

Underweight

$44.00

-2.72%

—

Maintain

2026-08-04

1 / 4

Avg Target

$58.42

vs Current ▲ +29.2% upside

Buy

13 analysts

Strong Buy 2Buy 9Hold 1Sell 1

Low $44.00

Current $45.23

High $70.00

Firm	Position	Target	Upside	Close	Action	Date
Freedom Capital Markets	Buy	$66.00	+45.92%	—	Maintain	26.09.15
UBS	Buy	$65.00	+43.71%	—	Maintain	26.09.09
Piper Sandler	Overweight	$54.00	+19.39%	—	Maintain	26.08.04
Stephens & Co.	Overweight	$55.00	+21.60%	—	Maintain	26.08.04
Morgan Stanley	Underweight	$44.00	-2.72%	—	Maintain	26.08.04

1 / 4

Price Information

Previous Close$43.60

Open$43.82

Day Range$43.50 - $46.17

52-Week Range$29.45 - $60.91

1-Year Change32.68%

Trading Volume

Volume966,523

Avg Volume (3mo)1,359,029

Valuation

Market Cap3.6B

Book Value$17.28

Shares Outstanding80,390,731

Financials

Revenue (TTM)561.9M

Net Income114.5M

EPS$1.40

EBITDA113.5M

Profitability

P/E Ratio32.31

P/B Ratio2.62

Return on Equity (ROE)8.77%

Return on Assets (ROA)4.09%

Profit Margin20.37%

EV/EBITDA28.11

Beta1.95

Dividend

Dividend Rate-

Dividend Yield0.00%

Technical

RSI(14)58.02

Company Overview

Veracyte, Inc. is a global diagnostics company that provides genomic tests to help diagnose cancer. Their main products include genomic classifiers for thyroid, prostate, bladder, and lung cancers, as well as a breast cancer assay. Veracyte aims to improve patient care by offering precise diagnostic solutions.

P/B

2.62

Price-to-Book

ROE

8.8%

Low return

Beta

1.95

High volatility

RSI(14)

58.0

Neutral zone

AI-generated summary. Not investment advice.

Veracyte, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks